Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Tulavi Therapeutics, Inc. See All Filings	D	2021-12-16 19:22:11 UTC
Amount To Be Raised $1,000,000 Associated Brokers / Dealers N/A CIK Number 0001738995 Filed Document 0001738995-21-000002 Exclusions or Exemptions 506b Accepted Date 2021-12-16 19:22:11 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Tulavi Therapeutics, Inc. See All Filings	D	2021-03-01 19:46:45 UTC
Amount To Be Raised $9,999,996 Associated Brokers / Dealers N/A CIK Number 0001738995 Filed Document 0001738995-21-000001 Exclusions or Exemptions 506b Accepted Date 2021-03-01 19:46:45 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Tulavi Therapeutics, Inc. See All Filings	D	2020-05-12 13:15:51 UTC
Amount To Be Raised $5,004,421 Associated Brokers / Dealers N/A CIK Number 0001738995 Filed Document 0001738995-20-000001 Exclusions or Exemptions 506b Accepted Date 2020-05-12 13:15:51 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Tulavi Therapeutics, Inc. See All Filings	D/A	2018-12-03 14:58:06 UTC
Amount To Be Raised $4,003,404 Associated Brokers / Dealers N/A CIK Number 0001738995 Filed Document 0001738995-18-000003 Exclusions or Exemptions 506c Accepted Date 2018-12-03 14:58:06 UTC Type of Offering D/A Industry Other Health Care Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Tulavi Therapeutics, Inc. See All Filings	D	2018-04-27 17:36:16 UTC
Amount To Be Raised $3,022,553 Associated Brokers / Dealers N/A CIK Number 0001738995 Filed Document 0001738995-18-000001 Exclusions or Exemptions 506c Accepted Date 2018-04-27 17:36:16 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity